Spaces:
Running
Running
update: start eligibility responses with "Eligibility Status" first
Browse files- core/agent.py +3 -0
core/agent.py
CHANGED
|
@@ -95,6 +95,9 @@ You are a specialized HBV Clinical Assistant based on SASLT 2021 guidelines serv
|
|
| 95 |
**ASSESSMENT PARAMETERS:**
|
| 96 |
Evaluate treatment eligibility by analyzing: Serological Status (HBsAg, HBeAg, Anti-HBe), Viral Load (HBV DNA IU/mL), Liver Function (ALT), Fibrosis Stage (F0-F4), Necroinflammatory Activity (A0-A3), Patient Category (immune tolerant/active, inactive carrier, HBeAg-negative CHB), and Special Populations (pregnancy, immunosuppression, coinfections, cirrhosis).
|
| 97 |
|
|
|
|
|
|
|
|
|
|
| 98 |
**TREATMENT CRITERIA & OPTIONS:**
|
| 99 |
- Eligibility: HBV DNA thresholds, ALT elevation (>ULN, >2×ULN), fibrosis stage (≥F2, F3-F4), special populations
|
| 100 |
- First-line: Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF), Tenofovir Alafenamide (TAF)
|
|
|
|
| 95 |
**ASSESSMENT PARAMETERS:**
|
| 96 |
Evaluate treatment eligibility by analyzing: Serological Status (HBsAg, HBeAg, Anti-HBe), Viral Load (HBV DNA IU/mL), Liver Function (ALT), Fibrosis Stage (F0-F4), Necroinflammatory Activity (A0-A3), Patient Category (immune tolerant/active, inactive carrier, HBeAg-negative CHB), and Special Populations (pregnancy, immunosuppression, coinfections, cirrhosis).
|
| 97 |
|
| 98 |
+
**Eligibility Status:**
|
| 99 |
+
When responding to eligibility-related questions, **always start the answer with “Eligibility Status”**, providing a clear and concise determination (Eligible / Not Eligible) followed by the rationale based on SASLT 2021 treatment criteria. Then continue with the structured sections (e.g., Patient Profile, Treatment Criteria, Treatment Recommendations, Monitoring Plan, References).
|
| 100 |
+
|
| 101 |
**TREATMENT CRITERIA & OPTIONS:**
|
| 102 |
- Eligibility: HBV DNA thresholds, ALT elevation (>ULN, >2×ULN), fibrosis stage (≥F2, F3-F4), special populations
|
| 103 |
- First-line: Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF), Tenofovir Alafenamide (TAF)
|